Cancer invasion and resistance: Interconnected processes of disease progression and therapy failure

Trends in Molecular Medicine

Volumn 18, Issue 1, 2012, Pages 13-26

  Alexander, Stephanie ^a,b   Friedl, Peter ^a,b,c  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CADHERIN; CD44V ANTIGEN; CHEMOKINE; CHEMOKINE RECEPTOR; CYTOKINE; CYTOKINE RECEPTOR; GROWTH FACTOR; GROWTH FACTOR RECEPTOR; INTEGRIN; INTEGRIN RECEPTOR; K RAS PROTEIN; MATRIX METALLOPROTEINASE; PROTEIN P53; RAS PROTEIN; REACTIVE OXYGEN METABOLITE; RHO FACTOR;

ANTIANGIOGENIC THERAPY; APOPTOSIS; CANCER CELL; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER INVASION; CANCER RADIOTHERAPY; CANCER RESISTANCE; CANCER SURVIVAL; CELL INFILTRATION; CELL MIGRATION; CELL SURVIVAL; DNA DAMAGE; DOWN REGULATION; EPITHELIAL MESENCHYMAL TRANSITION; HUMAN; HYPOXIA; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; METABOLIC STRESS; MOLECULARLY TARGETED THERAPY; NONHUMAN; ONCOGENE C H RAS; ONCOGENE N RAS; PLASTICITY; QUALITY OF LIFE; RADIOSENSITIVITY; REVIEW; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TUMOR MICROENVIRONMENT;

ANIMALS; DISEASE PROGRESSION; DRUG RESISTANCE, NEOPLASM; HUMANS; NEOPLASM INVASIVENESS; NEOPLASMS; SIGNAL TRANSDUCTION; TREATMENT FAILURE; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 81855199501     PISSN: 14714914     EISSN: 1471499X     Source Type: Journal    
DOI: 10.1016/j.molmed.2011.11.003     Document Type: Review

References (175)

1. Fidler I.J. The pathogenesis of cancer metastasis: the 'seed and soil' hypothesis revisited. Nat. Rev. Cancer 2003, 3:453-458.
2. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
3. Blagosklonny M.V. Oncogenic resistance to growth-limiting conditions. Nat. Rev. Cancer 2002, 2:221-225.
4. Meads M.B., et al. Environment-mediated drug resistance: a major contributor to minimal residual disease. Nat. Rev. Cancer 2009, 9:665-674.
5. Dean M., et al. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
6. Gospodinov A., et al. Nucleotide excision repair rates in rat tissues. Eur. J. Biochem. 2003, 270:1000-1005.
7. Gottesman M.M. Mechanisms of cancer drug resistance. Annu. Rev. Med. 2002, 53:615-627.
8. Jain R.K. Delivery of molecular and cellular medicine to solid tumors. Adv. Drug Deliv. Rev. 2001, 46:149-168.
9. Bertout J.A., et al. The impact of O2 availability on human cancer. Nat. Rev. Cancer 2008, 8:967-975.
10. Duda D.G., et al. CXCL12 (SDF1alpha)-CXCR4/CXCR7 pathway inhibition: an emerging sensitizer for anticancer therapies?. Clin. Cancer Res. 2011, 17:2074-2080.
11. De Bock K., et al. Antiangiogenic therapy, hypoxia, and metastasis: risky liaisons, or not?. Nat. Rev. Clin. Oncol. 2011, 8:393-404.
12. Kargiotis O., et al. Effects of irradiation on tumor cell survival, invasion and angiogenesis. J. Neurooncol. 2010, 100:323-338.
13. Garrido F., et al. " Hard" and " soft" lesions underlying the HLA class I alterations in cancer cells: implications for immunotherapy. Int. J. Cancer 2010, 127:249-256.
14. Singer K., et al. Suppression of T-cell responses by tumor metabolites. Cancer Immunol. Immunother. 2011, 60:425-431.
15. Devreotes P.N., Zigmond S.H. Chemotaxis in eukaryotic cells: a focus on leukocytes and Dictyostelium. Annu. Rev. Cell Biol. 1988, 4:649-686.
16. Hess D.A., Allan A.L. Migratory strategies of normal and malignant stem cells. Methods Mol Biol 2011, 750:25-44.
17. Yilmaz M., Christofori G. Mechanisms of motility in metastasizing cells. Mol. Cancer Res. 2010, 8:629-642.
18. Wyckoff J., et al. A paracrine loop between tumor cells and macrophages is required for tumor cell migration in mammary tumors. Cancer Res. 2004, 64:7022-7029.
19. Friedl P., Wolf K. Plasticity of cell migration: a multiscale tuning model. J. Cell Biol. 2010, 188:11-19.
20. Alexander S., et al. Dynamic imaging of cancer growth and invasion: a modified skin-fold chamber model. Histochem. Cell Biol. 2008, 130:1147-1154.
21. Friedl P., et al. Migration of coordinated cell clusters in mesenchymal and epithelial cancer explants in vitro. Cancer Res. 1995, 55:4557-4560.
22. Lelievre S., Larsen A.K. Development and characterization of suramin-resistant Chinese hamster fibrosarcoma cells: drug-dependent formation of multicellular spheroids and a greatly enhanced metastatic potential. Cancer Res. 1994, 54:3993-3997.
23. Weinstein R.S., et al. Relationship of the expression of the multidrug resistance gene product (P-glycoprotein) in human colon carcinoma to local tumor aggressiveness and lymph node metastasis. Cancer Res. 1991, 51:2720-2726.
24. Singh A., Settleman J. EMT, cancer stem cells and drug resistance: an emerging axis of evil in the war on cancer. Oncogene 2010, 29:4741-4751.
25. Voulgari A., Pintzas A. Epithelial-mesenchymal transition in cancer metastasis: mechanisms, markers and strategies to overcome drug resistance in the clinic. Biochim. Biophys. Acta 2009, 1796:75-90.
26. Cahill D.P., et al. Genetic instability and Darwinian selection in tumours. Trends Cell Biol. 1999, 9:M57-M60.
27. Hollstein M., et al. p53 mutations in human cancers. Science 1991, 253:49-53.
28. Whibley C., et al. p53 polymorphisms: cancer implications. Nat. Rev. Cancer 2009, 9:95-107.
29. Bates S., Vousden K.H. Mechanisms of p53-mediated apoptosis. Cell. Mol. Life Sci. 1999, 55:28-37.
30. Stambolic V., et al. Regulation of PTEN transcription by p53. Mol. Cell 2001, 8:317-325.
31. Liu D.P., et al. A common gain of function of p53 cancer mutants in inducing genetic instability. Oncogene 2010, 29:949-956.
32. Li Y., Prives C. Are interactions with p63 and p73 involved in mutant p53 gain of oncogenic function?. Oncogene 2007, 26:2220-2225.
33. Downward J. Targeting RAS signalling pathways in cancer therapy. Nat. Rev. Cancer 2003, 3:11-22.
34. Shaw R.J., Cantley L.C. Ras, PI(3)K and mTOR signalling controls tumour cell growth. Nature 2006, 441:424-430.
35. Madhunapantula S.V., Robertson G.P. Is B-Raf a good therapeutic target for melanoma and other malignancies?. Cancer Res. 2008, 68:5-8.
36. Ligresti G., et al. PIK3CA mutations in human solid tumors: role in sensitivity to various therapeutic approaches. Cell Cycle 2009, 8:1352-1358.
37. Stengel K., Zheng Y. Cdc42 in oncogenic transformation, invasion, and tumorigenesis. Cell Signal. 2011, 23:1415-1423.
38. Lurje G., Lenz H.J. EGFR signaling and drug discovery. Oncology 2009, 77:400-410.
39. Greulich H., Pollock P.M. Targeting mutant fibroblast growth factor receptors in cancer. Trends Mol. Med. 2011, 17:283-292.
40. Trusolino L., et al. MET signalling: principles and functions in development, organ regeneration and cancer. Nat. Rev. Mol. Cell Biol. 2010, 11:834-848.
41. Kim L.C., et al. Src kinases as therapeutic targets for cancer. Nat. Rev. Clin. Oncol. 2009, 6:587-595.
42. Duffy M.J., et al. Use of molecular markers for predicting therapy response in cancer patients. Cancer Treat. Rev. 2011, 37:151-159.
43. Sasaki N., et al. Bcl-2 is a better therapeutic target than c-Myc, but attacking both could be a more effective treatment strategy for B-cell lymphoma with concurrent Bcl-2 and c-Myc overexpression. Exp. Hematol. 2011, 39. 817-828.e1.
44. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
45. Graeber T.G., et al. Hypoxia-mediated selection of cells with diminished apoptotic potential in solid tumours. Nature 1996, 379:88-91.
46. Semenza G.L. Targeting HIF-1 for cancer therapy. Nat. Rev. Cancer 2003, 3:721-732.
47. De Toni-Costes F., et al. A New alpha5beta1 integrin-dependent survival pathway through GSK3beta activation in leukemic cells. PLoS ONE 2010, 5:e9807.
48. Eke I., et al. PINCH1 regulates Akt1 activation and enhances radioresistance by inhibiting PP1alpha. J. Clin. Invest. 2010, 120:2516-2527.
49. Shain K.H., et al. Beta1 integrin adhesion enhances IL-6-mediated STAT3 signaling in myeloma cells: implications for microenvironment influence on tumor survival and proliferation. Cancer Res. 2009, 69:1009-1015.
50. Duensing S., et al. Exposure to vinblastine modulates beta 1 integrin expression and in vitro binding to extracellular matrix molecules in a human renal carcinoma cell line. Invasion Metastasis 1996, 16:65-72.
51. Ohwada C., et al. CD44 and hyaluronan engagement promotes dexamethasone resistance in human myeloma cells. Eur. J. Haematol. 2008, 80:245-250.
52. Zoller M. CD44: can a cancer-initiating cell profit from an abundantly expressed molecule?. Nat. Rev. Cancer 2011, 11:254-267.
53. Westhoff M.A., et al. Identification of a novel switch in the dominant forms of cell adhesion-mediated drug resistance in glioblastoma cells. Oncogene 2008, 27:5169-5181.
54. Richter C.E., et al. High-grade, chemotherapy-resistant ovarian carcinomas overexpress epithelial cell adhesion molecule (EpCAM) and are highly sensitive to immunotherapy with MT201, a fully human monoclonal anti-EpCAM antibody. Am. J. Obstet. Gynecol. 2010, 203. 582.e1-582.e7.
55. Niedermeier M., et al. Isoform-selective phosphoinositide 3'-kinase inhibitors inhibit CXCR4 signaling and overcome stromal cell-mediated drug resistance in chronic lymphocytic leukemia: a novel therapeutic approach. Blood 2009, 113:5549-5557.
56. Yao Z., et al. TGF-beta IL-6 axis mediates selective and adaptive mechanisms of resistance to molecular targeted therapy in lung cancer. Proc. Natl. Acad. Sci. U.S.A. 2010, 107:15535-15540.
57. Dello Sbarba P., Rovida E. Transmodulation of cell surface regulatory molecules via ectodomain shedding. Biol. Chem. 2002, 383:69-83.
58. Lee C.T., et al. Hypoxia-driven immunosuppression: a new reason to use thermal therapy in the treatment of cancer?. Int. J. Hyperthermia 2010, 26:232-246.
59. Vazquez-Cintron E.J., et al. Tumor-induced disruption of proximal TCR-mediated signal transduction in tumor-infiltrating CD8+ lymphocytes inactivates antitumor effector phase. J. Immunol. 2010, 185:7133-7140.
60. Friedl P., Wolf K. Tumour-cell invasion and migration: diversity and escape mechanisms. Nat. Rev. Cancer 2003, 3:362-374.
61. Poincloux R., et al. Contractility of the cell rear drives invasion of breast tumor cells in 3D Matrigel. Proc. Natl. Acad. Sci. U.S.A. 2011, 108:1943-1948.
62. Sanz-Moreno V., et al. Rac activation and inactivation control plasticity of tumor cell movement. Cell 2008, 135:510-523.
63. Nabeshima K., et al. Cohort migration of carcinoma cells: differentiated colorectal carcinoma cells move as coherent cell clusters or sheets. Histol. Histopathol. 1999, 14:1183-1197.
64. Radunsky G.S., van Golen K.L. The current understanding of the molecular determinants of inflammatory breast cancer metastasis. Clin. Exp. Metastasis 2005, 22:615-620.
65. Hou J.M., et al. Circulating tumor cells as a window on metastasis biology in lung cancer. Am. J. Pathol. 2011, 178:989-996.
66. Sahai E. Illuminating the metastatic process. Nat. Rev. Cancer 2007, 7:737-749.
67. Wolf K., et al. Multi-step pericellular proteolysis controls the transition from individual to collective cancer cell invasion. Nat. Cell Biol. 2007, 9:893-904.
68. Parri M., Chiarugi P. Rac and Rho GTPases in cancer cell motility control. Cell Commun. Signal. 2010, 8:23.
69. Sahai E., Marshall C.J. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat. Cell Biol. 2003, 5:711-719.
70. Bosco E.E., et al. Rac1 GTPase: a " Rac" of all trades. Cell. Mol. Life Sci. 2009, 66:370-374.
71. Karlsson R., et al. Rho GTPase function in tumorigenesis. Biochim. Biophys. Acta 2009, 1796:91-98.
72. Friedl P., Wolf K. Proteolytic interstitial cell migration: a five-step process. Cancer Metastasis Rev. 2009, 28:129-135.
73. Vicente-Manzanares M., et al. Integrins in cell migration - the actin connection. J. Cell Sci. 2009, 122:199-206.
74. Ilina O., Friedl P. Mechanisms of collective cell migration at a glance. J. Cell Sci. 2009, 122:3203-3208.
75. Allinen M., et al. Molecular characterization of the tumor microenvironment in breast cancer. Cancer Cell 2004, 6:17-32.
76. Nomura S., et al. FGF10/FGFR2 signal induces cell migration and invasion in pancreatic cancer. Br. J. Cancer 2008, 99:305-313.
77. Hugo H., et al. Epithelial-mesenchymal and mesenchymal-epithelial transitions in carcinoma progression. J. Cell Physiol. 2007, 213:374-383.
78. Wolf K., et al. Compensation mechanism in tumor cell migration: mesenchymal-amoeboid transition after blocking of pericellular proteolysis. J. Cell Biol. 2003, 160:267-277.
79. Sanz-Moreno V., Marshall C.J. Rho-GTPase signaling drives melanoma cell plasticity. Cell Cycle 2009, 8:1484-1487.
80. Muller P.A., et al. p53 and its mutants in tumor cell migration and invasion. J. Cell Biol. 2011, 192:209-218.
81. Campbell P.M., Der C.J. Oncogenic Ras and its role in tumor cell invasion and metastasis. Semin. Cancer Biol. 2004, 14:105-114.
82. Dreissigacker U., et al. Oncogenic K-Ras down-regulates Rac1 and RhoA activity and enhances migration and invasion of pancreatic carcinoma cells through activation of p38. Cell Signal. 2006, 18:1156-1168.
83. Gulhati P., et al. mTORC1 and mTORC2 regulate EMT, motility, and metastasis of colorectal cancer via RhoA and Rac1 signaling pathways. Cancer Res. 2011, 71:3246-3256.
84. Thiery J.P., et al. Epithelial-mesenchymal transitions in development and disease. Cell 2009, 139:871-890.
85. Ansieau S., et al. TWISTing an embryonic transcription factor into an oncoprotein. Oncogene 2010, 29:3173-3184.
86. Barrallo-Gimeno A., Nieto M.A. The Snail genes as inducers of cell movement and survival: implications in development and cancer. Development 2005, 132:3151-3161.
87. Guerra L.E., et al. Invasive local recurrence increased after radiation therapy for ductal carcinoma in situ. Am. J. Surg. 2008, 196:552-555.
88. Dent P., et al. MAPK pathways in radiation responses. Oncogene 2003, 22:5885-5896.
89. Andarawewa K.L., et al. Ionizing radiation predisposes nonmalignant human mammary epithelial cells to undergo transforming growth factor beta induced epithelial to mesenchymal transition. Cancer Res. 2007, 67:8662-8670.
90. Kajiyama H., et al. Chemoresistance to paclitaxel induces epithelial-mesenchymal transition and enhances metastatic potential for epithelial ovarian carcinoma cells. Int. J. Oncol. 2007, 31:277-283.
91. Latifi A., et al. Cisplatin treatment of primary and metastatic epithelial ovarian carcinomas generates residual cells with mesenchymal stem cell-like profile. J. Cell Biochem. 2011, 112:2850-2864.
92. Shah A.N., et al. Development and characterization of gemcitabine-resistant pancreatic tumor cells. Ann. Surg. Oncol. 2007, 14:3629-3637.
93. Yang A.D., et al. Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines. Clin. Cancer Res. 2006, 12:4147-4153.
94. Sharma S.V., et al. Epidermal growth factor receptor mutations in lung cancer. Nat. Rev. Cancer 2007, 7:169-181.
95. Engelman J.A., et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007, 316:1039-1043.
96. Wheeler D.L., et al. Mechanisms of acquired resistance to cetuximab: role of HER (ErbB) family members. Oncogene 2008, 27:3944-3956.
97. Ebos J.M., et al. Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. Cancer Cell 2009, 15:232-239.
98. Rubenstein J.L., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2:306-314.
99. Casanovas O., et al. Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 2005, 8:299-309.
100. Narayana A., et al. Antiangiogenic therapy using bevacizumab in recurrent high-grade glioma: impact on local control and patient survival. J. Neurosurg. 2009, 110:173-180.
101. Paez-Ribes M., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
102. You W.K., et al. VEGF and c-Met blockade amplify angiogenesis inhibition in pancreatic islet cancer. Cancer Res. 2011, 71:4758-4768.
103. Sansing H.A., et al. Integrin alphabeta1, alphavbeta, alpha6beta effectors p130Cas, Src and talin regulate carcinoma invasion and chemoresistance. Biochem. Biophys. Res. Commun. 2011, 406:171-176.
104. Giese A., et al. Cost of migration: invasion of malignant gliomas and implications for treatment. J. Clin. Oncol. 2003, 21:1624-1636.
105. Molina J.R., et al. Invasive glioblastoma cells acquire stemness and increased Akt activation. Neoplasia 2010, 12:453-463.
106. Goplen D., et al. alphaB-crystallin is elevated in highly infiltrative apoptosis-resistant glioblastoma cells. Am. J. Pathol. 2010, 177:1618-1628.
107. Mariani L., et al. Glioma cell motility is associated with reduced transcription of proapoptotic and proliferation genes: a cDNA microarray analysis. J. Neurooncol. 2001, 53:161-176.
108. Mariani L., et al. Death-associated protein 3 (Dap-3) is overexpressed in invasive glioblastoma cells in vivo and in glioma cell lines with induced motility phenotype in vitro. Clin. Cancer Res. 2001, 7:2480-2489.
109. Jankowski K., et al. Both hepatocyte growth factor (HGF) and stromal-derived factor-1 regulate the metastatic behavior of human rhabdomyosarcoma cells, but only HGF enhances their resistance to radiochemotherapy. Cancer Res. 2003, 63:7926-7935.
110. Fan S., et al. The cytokine hepatocyte growth factor/scatter factor inhibits apoptosis and enhances DNA repair by a common mechanism involving signaling through phosphatidyl inositol 3' kinase. Oncogene 2000, 19:2212-2223.
111. Sekharam M., et al. Insulin-like growth factor 1 receptor enhances invasion and induces resistance to apoptosis of colon cancer cells through the Akt/Bcl-x(L) pathway. Cancer Res. 2003, 63:7708-7716.
112. Hassan S., et al. CXCR4 peptide antagonist inhibits primary breast tumor growth, metastasis and enhances the efficacy of anti-VEGF treatment or docetaxel in a transgenic mouse model. Int. J. Cancer 2011, 129:225-232.
113. Uchida D., et al. Blockade of CXCR4 in oral squamous cell carcinoma inhibits lymph node metastases. Eur. J. Cancer 2011, 47:452-459.
114. Rhodes L.V., et al. Cytokine receptor CXCR4 mediates estrogen-independent tumorigenesis, metastasis, and resistance to endocrine therapy in human breast cancer. Cancer Res. 2011, 71:603-613.
115. Johnson-Holiday C., et al. CCL25 mediates migration, invasion and matrix metalloproteinase expression by breast cancer cells in a CCR9-dependent fashion. Int. J. Oncol. 2011, 38:1279-1285.
116. Johnson-Holiday C., et al. CCR9-CCL25 interactions promote cisplatin resistance in breast cancer cell through Akt activation in a PI3K-dependent and FAK-independent fashion. World J. Surg. Oncol. 2011, 9:46.
117. Santiskulvong C., et al. Dual targeting of phosphoinositide 3-kinase and mammalian target of rapamycin using NVP-BEZ235 as a novel therapeutic approach in human ovarian carcinoma. Clin. Cancer Res. 2011, 17:2373-2384.
118. Roccaro A.M., et al. Dual targeting of the PI3K/Akt/mTOR pathway as an antitumor strategy in Waldenstrom macroglobulinemia. Blood 2010, 115:559-569.
119. Nagaraj N.S., et al. Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth. Clin. Cancer Res. 2011, 17:483-493.
120. De Wever O., et al. Stromal myofibroblasts are drivers of invasive cancer growth. Int. J. Cancer 2008, 123:2229-2238.
121. Sica A., et al. Macrophage polarization in tumour progression. Semin. Cancer Biol. 2008, 18:349-355.
122. Dolcetti L., et al. Myeloid-derived suppressor cell role in tumor-related inflammation. Cancer Lett. 2008, 267:216-225.
123. Charafe-Jauffret E., et al. Defining the molecular biology of inflammatory breast cancer. Semin. Oncol. 2008, 35:41-50.
124. Minamiya Y., et al. The CRP 1846T/T genotype is associated with a poor prognosis in patients with non-small cell lung cancer. Tumour Biol. 2010, 31:673-679.
125. Wu Y., et al. Prognostic role of systemic inflammatory response in renal cell carcinoma: a systematic review and meta-analysis. J. Cancer Res. Clin. Oncol. 2011, 137:887-896.
126. Asaoka Y., et al. New targeted therapies for gastric cancer. Expert Opin. Investig. Drugs 2011, 20:595-604.
127. Pantel K., Alix-Panabieres C. Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol. Med. 2010, 16:398-406.
128. Cordes N., Park C.C. beta1 integrin as a molecular therapeutic target. Int. J. Radiat. Biol. 2007, 83:753-760.
129. Desgrosellier J.S., Cheresh D.A. Integrins in cancer: biological implications and therapeutic opportunities. Nat. Rev. Cancer 2010, 10:9-22.
130. Pennacchietti S., et al. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3:347-361.
131. Chiavarina B., et al. HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: autophagy drives compartment-specific oncogenesis. Cell Cycle 2010, 9:3534-3551.
132. Rozhin J., Sameni M., Ziegler G., Sloane B.F. Pericellular pH affects distribution and secretion of cathepsin B in malignant cells. Cancer Res. 1994, 54:6517-6525.
133. Gatenby R.A., Gillies R.J. Why do cancers have high aerobic glycolysis?. Nat. Rev. Cancer 2004, 4:891-899.
134. Bonuccelli G., et al. The reverse Warburg effect: glycolysis inhibitors prevent the tumor promoting effects of caveolin-1 deficient cancer associated fibroblasts. Cell Cycle 2010, 9:1960-1971.
135. Cicha I., Goppelt-Struebe M. Connective tissue growth factor: context-dependent functions and mechanisms of regulation. Biofactors 2009, 35:200-208.
136. Santibanez J.F., et al. TGF-beta/TGF-beta receptor system and its role in physiological and pathological conditions. Clin. Sci. (Lond.) 2011, 121:233-251.
137. Raman D., et al. Chemokines in health and disease. Exp. Cell Res. 2011, 317:575-589.
138. Hofer S.O., et al. The effect of surgical wounding on tumour development. Eur. J. Surg. Oncol. 1999, 25:231-243.
139. Shiao S.L., Coussens L.M. The tumor-immune microenvironment and response to radiation therapy. J. Mammary Gland Biol. Neoplasia 2010, 15:411-421.
140. Gilbert L.A., Hemann M.T. DNA damage-mediated induction of a chemoresistant niche. Cell 2010, 143:355-366.
141. Shaked Y., et al. Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. Cancer Cell 2008, 14:263-273.
142. Faught W., Fung Kee Fung M. Port site recurrences following laparoscopically managed early stage endometrial cancer. Int. J. Gynecol. Cancer 1999, 9:256-258.
143. Winston C.B., et al. Recurrent gallbladder carcinoma along laparoscopic cholecystectomy port tracks: CT demonstration. Radiology 1999, 212:439-444.
144. Langer C., Soria J.C. The role of anti-epidermal growth factor receptor and anti-vascular endothelial growth factor therapies in the treatment of non-small-cell lung cancer. Clin. Lung Cancer 2010, 11:82-90.
145. De Bacco F., et al. Induction of MET by ionizing radiation and its role in radioresistance and invasive growth of cancer. J. Natl. Cancer Inst. 2011, 103:645-661.
146. Tartour E., et al. Angiogenesis and immunity: a bidirectional link potentially relevant for the monitoring of antiangiogenic therapy and the development of novel therapeutic combination with immunotherapy. Cancer Metast. Rev. 2011, 30:83-95.
147. Maira S.M., et al. PI3K inhibitors for cancer treatment: where do we stand?. Biochem. Soc. Trans. 2009, 37:265-272.
148. McCormick F. Cancer therapy based on oncogene addiction. J. Surg. Oncol. 2011, 103:464-467.
149. Yap J.L., et al. Small-molecule inhibitors of the ERK signaling pathway: towards novel anticancer therapeutics. Chem. Med. Chem. 2011, 6:38-48.
150. Konstantinidou G., et al. Dual phosphoinositide 3-kinase/mammalian target of rapamycin blockade is an effective radiosensitizing strategy for the treatment of non-small cell lung cancer harboring K-RAS mutations. Cancer Res. 2009, 69:7644-7652.
151. Eke I., Cordes N. Dual targeting of EGFR and focal adhesion kinase in 3D grown HNSCC cell cultures. Radiother. Oncol. 2011, 99:279-286.
152. Alexandrova A., et al. Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization. Oncogene 2000, 19:5826-5830.
153. Kharait S., et al. Protein kinase Cdelta signaling downstream of the EGF receptor mediates migration and invasiveness of prostate cancer cells. Biochem. Biophys. Res. Commun. 2006, 343:848-856.
154. Zhou W., et al. STAT3 is required but not sufficient for EGF receptor-mediated migration and invasion of human prostate carcinoma cell lines. Br. J. Cancer 2006, 95:164-171.
155. Eswarakumar V.P., et al. Cellular signaling by fibroblast growth factor receptors. Cytokine Growth Factor Rev. 2005, 16:139-149.
156. De Laurentiis A., et al. The catalytic class I(A) PI3K isoforms play divergent roles in breast cancer cell migration. Cell Signal. 2011, 23:529-541.
157. Tsapara A., et al. The RhoA activator GEF-H1/Lfc is a transforming growth factor-beta target gene and effector that regulates alpha-smooth muscle actin expression and cell migration. Mol. Biol. Cell 2010, 21:860-870.
158. Hynes R.O. Integrins: bidirectional, allosteric signaling machines. Cell 2002, 110:673-687.
159. Cordes N., Meineke V. Cell adhesion-mediated radioresistance (CAM-RR). Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther. Onkol. 2003, 179:337-344.
160. Damiano J.S., et al. Cell adhesion mediated drug resistance (CAM-DR): role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93:1658-1667.
161. Hegerfeldt Y., et al. Collective cell movement in primary melanoma explants: plasticity of cell-cell interaction, beta1-integrin function, and migration strategies. Cancer Res. 2002, 62:2125-2130.
162. Toole B.P., Slomiany M.G. Hyaluronan: a constitutive regulator of chemoresistance and malignancy in cancer cells. Semin. Cancer Biol. 2008, 18:244-250.
163. Maaser K., et al. Functional hierarchy of simultaneously expressed adhesion receptors: integrin alpha2beta1 but not CD44 mediates MV3 melanoma cell migration and matrix reorganization within three-dimensional hyaluronan-containing collagen matrices. Mol. Biol. Cell 1999, 10:3067-3079.
164. Brembeck F.H., et al. Balancing cell adhesion and Wnt signaling, the key role of beta-catenin. Curr. Opin. Genet. Dev. 2006, 16:51-59.
165. Reynolds A.B., Roczniak-Ferguson A. Emerging roles for p120-catenin in cell adhesion and cancer. Oncogene 2004, 23:7947-7956.
166. Weber G.F., et al. Integrins and cadherins join forces to form adhesive networks. J. Cell Sci. 2011, 124:1183-1193.
167. Maruthamuthu V., et al. Conserved F-actin dynamics and force transmission at cell adhesions. Curr. Opin. Cell Biol. 2010, 22:583-588.
168. Vitorino P., Meyer T. Modular control of endothelial sheet migration. Genes Dev. 2008, 22:3268-3281.
169. Friedl P., Alexander S. Cancer invasion and the microenvironment: plasticity and reciprocity. Cell 2011, 147:992-1009.
170. Zhang B., et al. Rac1 inhibits apoptosis in human lymphoma cells by stimulating Bad phosphorylation on Ser-75. Mol. Cell. Biol. 2004, 24:6205-6214.
171. Heasman S.J., Ridley A.J. Mammalian Rho GTPases: new insights into their functions from in vivo studies. Nat. Rev. Mol. Cell Biol. 2008, 9:690-701.
172. Kulbe H., et al. The chemokine network in cancer - much more than directing cell movement. Int. J. Dev. Biol. 2004, 48:489-496.
173. Rattigan Y., et al. Interleukin 6 mediated recruitment of mesenchymal stem cells to the hypoxic tumor milieu. Exp. Cell Res. 2010, 316:3417-3424.
174. Sabeh F., et al. Protease-dependent versus -independent cancer cell invasion programs: three-dimensional amoeboid movement revisited. J. Cell Biol. 2009, 185:11-19.
175. Wolf K., Friedl P. Molecular mechanisms of cancer cell invasion and plasticity. Br. J. Dermatol. 2006, 154(Suppl. 1):11-15.